Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulse rhythm01:30

Pulse rhythm

1.6K
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
1.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

414
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
414
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Holter Monitor: 24-Hour Monitoring01:23

Holter Monitor: 24-Hour Monitoring

4.2K
Holter monitoring is a continuous electrocardiography (ECG) recording that tracks the heart's electrical activity over an extended period, generally 24 to 48 hours. This noninvasive diagnostic tool detects irregular heart rhythms that may not be captured during a standard ECG performed in a clinical setting.DeviceThe Holter monitor is a portable, small device connected to several electrodes on the patient's chest. These electrodes detect the heart's electrical signals and transmit them to the...
4.2K
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Imaging Studies for Cardiovascular System IV: CMRI01:21

Imaging Studies for Cardiovascular System IV: CMRI

515
Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
515

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is There a Golden Hour for Thrombectomy in Intermediate-Risk Pulmonary Embolism? Insights From SYMPHONY-PE.

Circulation. Cardiovascular interventions·2026
Same author

C-Reactive Protein and Long-Term Risk of Death in Patients with Myocardial Infarction.

Cardiology·2026
Same author

Real-world analysis of outcomes of patients undergoing coronary intravascular lithotripsy versus atherectomy for calcified coronary artery disease: findings from the TriNetX database.

The Journal of invasive cardiology·2026
Same author

Ischemic Stroke Polygenic Risk Score and Recurrent Cardiac and Cerebrovascular Events After Coronary Artery Revascularization.

European journal of preventive cardiology·2026
Same author

Cardiovascular Outcomes With GLP-1 Receptor Agonists in Patients With Diabetes or Obesity Undergoing Transcatheter Aortic Valve Replacement.

The Canadian journal of cardiology·2026
Same author

Development of an Integrated Monogenic and Polygenic Risk Assessment Tool for Coronary Artery Disease and Its Application in a Community-Based Health Care Biobank.

Circulation. Genomic and precision medicine·2026

Related Experiment Video

Updated: Mar 26, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K

Current status of data on cangrelor.

Arman Qamar1, Deepak L Bhatt1

  • 1Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA.

Pharmacology & Therapeutics
|January 24, 2016
PubMed
Summary

Cangrelor, an intravenous P2Y12 inhibitor, effectively reduces ischemic events in percutaneous coronary intervention (PCI) patients without increasing bleeding. It offers rapid action and reversibility, addressing limitations of oral antiplatelet therapies.

Keywords:
Acute coronary syndromeAntiplatelet therapyCangrelorCoronary artery diseaseP2Y12 receptor inhibitionPercutaneous coronary intervention (PCI)

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Related Experiment Videos

Last Updated: Mar 26, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • P2Y12 receptor inhibition plus aspirin is standard for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
  • Periprocedural thrombotic complications remain a significant concern despite current antithrombotic therapies.
  • Oral P2Y12 inhibitors have limitations including delayed onset/offset and inter-individual variability.

Purpose of the Study:

  • To review the evidence for cangrelor, an intravenous P2Y12 inhibitor, in PCI.
  • To analyze cangrelor's role in contemporary antithrombotic practice.

Main Methods:

  • Comprehensive analysis of current evidence.
  • Review of large randomized trials comparing cangrelor to clopidogrel in PCI patients.

Main Results:

  • Cangrelor demonstrated a significant reduction in ischemic events.
  • No increase in severe bleeding was observed compared to clopidogrel.
  • Cangrelor offers potent, rapidly reversible platelet inhibition.

Conclusions:

  • Cangrelor is approved as an adjunct to PCI for reducing MI, revascularization, and stent thrombosis in specific patient groups.
  • Its rapid onset and reversibility make it a valuable alternative to oral P2Y12 inhibitors.
  • Cangrelor represents a significant advancement in managing thrombotic risk during PCI.